Incruse Ellipta and Zydone

• Generic Name: umeclidinium
• Dosage Forms: aerosol, powder
• Other Brand Names: Incruse Ellipta

Incruse Ellipta (umeclidinium) is an anticholinergic that works by relaxing muscles in the airways to improve breathing.

Incruse Ellipta is used to prevent airflow obstruction and reduce flare-ups in adults with COPD (chronic obstructive pulmonary disease, including bronchitis and emphysema.

Incruse Ellipta is for use only in people with COPD and should not be used to treat asthma.

• Generic Name: acetaminophen / hydrocodone
• Dosage Forms: tablet
• Other Brand Names: Anexsia, Dolorex Forte, Hycet, Liquicet, Lorcet, Lortab, Maxidone, Norco, Polygesic, Stagesic, Vicodin, Xodol, Zamicet, Zydone, Verdrocet, Lortab 10/325, Lortab 5/325, Lortab 75/325, Lortab Elixir, Zyfrel

Hydrocodone and acetaminophen combination is used to relieve pain severe enough to require opioid treatment and when other pain medicines did not work well enough or cannot be tolerated.

Acetaminophen is used to relieve pain and reduce fever in patients. It does not become habit-forming when taken for a long time. But acetaminophen may cause other unwanted effects when taken in large doses, including liver damage.

Hydrocodone belongs to the group of medicines called narcotic analgesics (pain medicines). It acts on the central nervous system (CNS) to relieve pain, and stops or prevents cough.

When hydrocodone is used for a long time, it may become habit-forming, causing mental or physical dependence. However, people who have continuing pain should not let the fear of dependence keep them from using narcotics to relieve their pain. Mental dependence (addiction) is not likely to occur when narcotics are used for this purpose. Physical dependence may lead to withdrawal side effects if treatment is stopped suddenly. However, severe withdrawal side effects can usually be prevented by gradually reducing the dose over a period of time before treatment is stopped completely.

This medicine is available only under a restricted distribution program called the Opioid Analgesic REMS (Risk Evaluation and Mitigation Strategy) program.